See HealthCap’s activity on LinkedIn

HealthCap reposted this

President and Chief Executive Officer at Carisma Therapeutics

4mo

The FDA's Fast Track Designation for CT-0525 is a pivotal milestone for Carisma, reflecting the potential of our therapy to make a significant impact in the treatment of solid tumors.

Carisma Therapeutics

14,459 followers

4mo

We are excited to announce that that the U.S. FDA has granted Fast Track Designation for CT-0525, an ex vivo gene-modified autologous CAR-Monocyte cellular therapy intended to treat HER2-overexpressing solid tumors. This marks a significant milestone for Carisma, highlighting the FDA's recognition of the serious and life-threatening nature of these malignancies and the potential of CT-0525 to meet this critical medical need. Read more in the press release here: https://lnkd.in/gqd93wxq #immunotherapy #oncology

9 Comments

John Grady

Senior Vice President, Northeast Region Executive at Wexford Science & Technology, LLC

4mo

Great news for your team and patients, Steve.

Chris Giffin

President & Chief Operating Officer

4mo

Congratulations, Steven, and good news for patients.

Geoffrey Glass

Chief Executive Officer

4mo

Steven Kelly congrats to you and your team!

Jay Seemann

Biotech & Pharma Global, Executive Leader & Commercial Strategy | Sales, Marketing, Market Access | Therapeutics (Rx) & Clinical Molecular Diagnostics (Dx) | Oncology & Specialty

4mo

Congrats Steve, best of luck!